Legal & General Group
MTNB icon

Legal & General Group’s Matinas BioPharma MTNB Stock Holding History

Legal & General Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-276
Closed -$11K – 3371
2018
Q1 		$11K Hold
276
– – ﹤0.01% 3209
2017
Q4 		$16K Buy
276
+120
+77% +$7.72K ﹤0.01% 3182
2017
Q3 		$10K Hold
156
– – ﹤0.01% 3277
2017
Q2 		$13K Buy
+156
New +$20.9K ﹤0.01% 3285

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Legal & General Group's MTNB Position: Q2 2018 in Review

Legal & General Group sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 276 shares — an estimated $11K sold.

Legal & General Group first reported a position in MTNB in Q2 2017 and held it in 4 quarters. The position peaked at $16K in Q4 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

  • Legal & General Group reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 276 Matinas BioPharma shares in Q2 2018, an estimated $11K.
  • Legal & General Group first reported a position in Matinas BioPharma in Q2 2017 and held it in 4 quarters.
  • Legal & General Group's Matinas BioPharma position peaked at $16K in Q4 2017.
  • 39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.